Finoriq research workspace
Adaptive Biotechnologies Corp (ADPT) News
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform. Review ADPT recent headlines, source links, and company news on Finoriq.
Company Snapshot
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Company
- Adaptive Biotechnologies Corp (ADPT)
- Ticker
- ADPT
- Market Cap
- $3.5B
- Latest Price
- $21.85
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.